(secondQuint)Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer.

 A multicenter randomized phase III clinical trial of gemcitabine in combination with capecitabine versus gemcitabine plus carboplatin as first-line treatment in triple-negative recurrent or metastatic breast cancer.

The primary endpoints of the study is progression free survival (PFS).

 The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.

.

 Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer@highlight

Gemcitabine plus carboplatin in recurrent or metastatic breast cancer is a recommended scheme in National Comprehensive Cancer Network (NCCN) guideline.

 gemcitabine in combination with capecitabine is also effective in Metastatic Breast Cancer (MBC) in some clinical study with small sample.

